Rapport Therapeutics (NASDAQ:RAPP) Sees Large Volume Increase

Rapport Therapeutics (NASDAQ:RAPP) shares saw an uptick in trading volume on Wednesday . 106,601 shares were traded during mid-day trading, a decline of 45% from the previous session’s volume of 195,283 shares.The stock last traded at $21.00 and had previously closed at $20.98.

Analysts Set New Price Targets

RAPP has been the subject of a number of research reports. TD Cowen initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating for the company. Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price on the stock.

Rapport Therapeutics Price Performance

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, Director James Healy purchased 44,032 shares of the stock in a transaction dated Monday, July 1st. The stock was bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the transaction, the director now directly owns 40,851 shares in the company, valued at $1,001,666.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.